Multidisciplinary Case Conference in Psoriatic Arthritis: Enhancing Outcomes with Oral Targeted Therapies

What you'll learn

Course overview

Psoriatic arthritis (PsA) is a chronic, immune-mediated disease that develops in up to 30% of patients with psoriasis. Characterized by inflammation of the skin, nails, entheses, and peripheral and axial joints, PsA can result in progressive joint damage, functional disability, and impaired quality of life (Kang & Coates, 2025). The advent of biologic and targeted synthetic agents directed at mediators of specific cytokine pathways-including PDE4, JAK, and TYK2-has significantly improved patient outcomes while providing the flexibility and treatment personalization potential of oral therapy (Goupille et al, 2024; Tsiogkas et al, 2025). In order to optimize the efficacy and safety of targeted therapy, multidisciplinary collaboration between members of the dermatology and rheumatology teams is crucial. In this Multidisciplinary Care Conference, Tina Bhutani-Jacques, MD, MAS, FAAD, Chief Executive Officer of Synergy Dermatology and Associate Clinical Professor at UCSF Dermatology, and Christopher Ritchlin, MD, MPH, Professor in the Division of Allergy, Immunology, and Rheumatology at the University of Rochester Medical Center, will explore strategies for enhancing outcomes with oral targeted therapies in psoriatic arthritis.